Interleukin 6 Knockout Prevents Angiotensin II Hypertension: Role of Renal Vasoconstriction and Janus Kinase 2/signal Transducer and Activator of Transcription 3 Activation
Overview
Authors
Affiliations
Chronic angiotensin II (Ang II) infusion stimulates interleukin (IL) 6 release, and we and others have shown that preventing the increase in IL-6 significantly attenuates Ang II hypertension. This study measured renal blood flow (RBF) chronically, using Transonic flow probes in wild-type (WT) and IL-6 knockout (KO) mice, to determine the role of RBF regulation in that response. Ang II infusion at 200, 800, and 3600 ng/kg per minute caused a dose-dependent decrease in RBF in WT mice, and the response at 800 ng/kg per minute was compared between WT and IL-6 KO mice. Ang II infusion increased plasma IL-6 concentration in WT mice and increased mean arterial pressure (19 h/d with telemetry) from 113±4 to 149±4 mm Hg (Δ36 mm Hg) over the 7-day infusion period, and that effect was blocked in IL-6 KO mice (119±7 to 126±7 mm Hg). RBF decreased to an average of 61±8% of control over the 7-day period (control: 0.86±0.02 mL/min) in the WT mice; however, the average decrease to 72±6% of control (control: 0.88±0.02 mL/min) in the KO mice was not significantly different. There also was no difference in afferent arteriolar constriction by Ang II in blood-perfused juxtamedullary nephrons in WT versus KO mice. Phosphorylation of janus kinase 2 and signal transducer and activator of transcription 3 in renal cortex homogenates increased significantly in Ang II-infused WT mice, and that effect was prevented completely in Ang II-infused IL-6 KO mice. These data suggest that IL-6-dependent activation of the renal janus kinase 2/signal transducer and activator of transcription 3 pathway plays a role in Ang II hypertension but not by mediating the effect of Ang II to decrease total RBF.
IL-6 and diabetic kidney disease.
Zhang L, Xu F, Hou L Front Immunol. 2025; 15:1465625.
PMID: 39749325 PMC: 11693507. DOI: 10.3389/fimmu.2024.1465625.
Targeting inerleukin-6 for renoprotection.
Gubernatorova E, Samsonov M, Drutskaya M, Lebedeva S, Bukhanova D, Materenchuk M Front Immunol. 2024; 15:1502299.
PMID: 39723211 PMC: 11668664. DOI: 10.3389/fimmu.2024.1502299.
Immune Mechanisms in Hypertension.
Harrison D, Patrick D Hypertension. 2024; 81(8):1659-1674.
PMID: 38881474 PMC: 11254551. DOI: 10.1161/HYPERTENSIONAHA.124.21355.
Sex-specific relationships of inflammatory biomarkers with blood pressure in older adults.
Sulicka-Grodzicka J, Wizner B, Zdrojewski T, Mossakowska M, Puzianowska-Kuznicka M, Chudek J Geroscience. 2024; 46(5):4603-4614.
PMID: 38720047 PMC: 11335980. DOI: 10.1007/s11357-024-01170-8.
Immunomodulatory Activity of Cytokines in Hypertension: A Vascular Perspective.
Dos Passos R, Santos C, Priviero F, Briones A, Tostes R, Webb R Hypertension. 2024; 81(7):1411-1423.
PMID: 38686582 PMC: 11168883. DOI: 10.1161/HYPERTENSIONAHA.124.21712.